Update on the use of dutasteride in the management of benign prostatic hypertrophy

Figures & data

Table 1 Pharmacokinetics of dutasteride 0.5 mg/day

Bioavailability	60%
Steady state	3 months
Peak serum concentration	2–3 hours
Volume of distribution	511 liters
Elimination half-life	5 weeks

Figure 1 Dutasteride structural formula.

Table 2 Adverse events from dutasteride efficacy and safety study

	Dutasteride	Placebo
Impotence	7.3%	4.0%
Decreased libido	4.2%	2.1%
Ejaculation disorder	2.2%	0.8%
Gynecomastia	2.3%	0.7%